2026-07-21T13:56:27Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/51612024-10-31T11:45:02Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605col_20.500.12105_19607

00925njm 22002777a 4500 dc de la Cuesta, Fernando author Baldan-Martin, Montserrat author Moreno-Luna, Rafael author Alvarez-Llamas, Gloria author Gonzalez-Calero, Laura author Mourino-Alvarez, Laura author Sastre-Oliva, Tamara author Lopez, Juan Antonio author Vazquez, Jesus author Ruiz-Hurtado, Gema author Segura, Julian author Vivanco, Fernando author Ruilope, Luis M author Barderas, Maria G author 2017 Despite of the great advances in anti-hypertensive therapies, many patients under Renin-Angiotensin-System (RAS) suppression develop albuminuria, which is a clear indicator of therapeutic inefficiency. Hence, indicators of vascular function are needed to assess patients' condition and help deciding future therapies. Proteomic analysis of circulating extracellular vesicles (EVs) showed two proteins, kalirin and chromodomain-helicase-DNA-binding protein 7 (CHD7), increased in albuminuric patients. A positive correlation of both with the expression of the endothelial activation marker E-selectin was found in EVs. In vitro analysis using TNFa-treated adult human endothelial cells proved their involvement in endothelial cell activation. Hence, we propose protein levels of kalirin and CHD7 in circulating EVs as novel endothelial dysfunction markers to monitor vascular condition in hypertensive patients with albuminuria. Oncotarget. 2017; 8(9):15553-15562 10.18632/oncotarget.14948 1949-2553 Oncotarget 28152519 http://hdl.handle.net/20.500.12105/5161 Extracellular vesicles Proteomics Endothelial dysfunction Hypertension Albuminuria ANGIOTENSIN SYSTEM SUPPRESSION OXIDATIVE STRESS CELLS MICROALBUMINURIA DISEASE Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria